SEARCH

SEARCH BY CITATION

References

  • ANKER, S.D. & COATS, J.S. (1999). Cardiac cachexia. A syndrome with impaired survival and immune and neuroendocrine activation. Chest, 115, 836847.
  • ANKER, S.D., PONIKOWSKI, P., VARNEY, S., CHUA, T.P., CLARK, A.L., WEBB-PEPLOE, K.M., HARRINGTON, D., KOX, W.J., POOLE-WILSON, P.A. & COATS, A.J.S. (1997). Wasting as independent risk factor for mortality in chronic heart failure. Lancet, 349, 10501053.
  • ARGILÉS, J.M., BUSQUETS, S., FELIPE, A. & LÓPEZ-SORIANO, F.J. (2005a). Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int. J. Biochem. Cell. Biol., 37, 10841104.
  • ARGILÉS, J.M., BUSQUETS, S., FELIPE, A. & LÓPEZ-SORIANO, F.J. (2005b). The pivotal role of cytokines in muscle wasting during cancer. Int. J. Biochem. Cell. Biol., 37, 20362046.
  • BAKER, J.G. (2005). The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br. J. Pharmacol., 144, 317322.
  • BRODDE, O.-E. (1991). β1- and β2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol. Rev., 43, 203242.
  • BUSQUETS, S., FIGUERAS, M.T., FUSTER, G., ALMENDRO, V., MOORE-CARRASCO, R., AMETLLER, W., ARGILÉS, J.M. & LÓPEZ-SORIANO, F.J. (2004). Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res, 64, 67256731.
  • CAZZOLA, M., IMPERATORE, F., SALZILLO, A., DI PERNA, F., CALDERARO, F., IMPERATORE, A. & MATERA, M.G. (1998). Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest, 114, 411415.
  • DORN II, G.W., TEPE, N.M., LORENZ, J.N., KOCH, W.J. & LIGGETT, S.B. (1999). Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc. Natl. Acad.Sci. U.S.A., 96, 64006405.
  • ENGELHARDT, S., HEIN, L., WIESMANN, F. & LOHSE, M.J. (1999). Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 96, 70597064.
  • FOWLER, M.B., TIMMIS, A.D., CRICK, J.P., VINCENT, R. & CHAMBERLAIN, D.A. (1982). Comparison of haemodynamic responses to dobutamine and salbutamol in cardiogenic shock after acute myocardial infarction. Br. Med. J., 284, 7376.
  • HALL, J.A., KAUMANN, A.J. & BROWN, M.J. (1990). Selective β1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through β2-adrenoceptors in human atrial myocardium. Circ. Res., 66, 16101623.
  • HALL, J.A., PETCH, M.C. & BROWN, M.J. (1989). Intracoronary injections of salbutamol demonstrate the presence of functional β2-adrenoceptors in the human heart. Circ. Res., 65, 546553.
  • HANSEN, M.J., GUALANO, R.C., BOZINOVSKI, S., VLAHOS, R. & ANDERSON, G.P. (2006). Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease). Pharmacol. Ther., 109, 162172.
  • HINKLE, R.T., HODGE, K.M.B., CODY, B.S., SHELDON, R.J., KOBILKA, B.K. & ISFORT, R.J. (2002). Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the β2-adrenergic receptor. Muscle Nerve, 25, 729734.
  • HOFFMANN, C., LEITZ, M.R., OBERDORF-MAASS, S., LOHSE, M.J. & KLOTZ, K.-N. (2004). Comparative pharmacology of human β-adrenergic receptor subtypes – characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol., 369, 151159.
  • KAUMANN, A., BARTEL, S., MOLENAAR, P., SANDERS, L., BURRELL, K., VETTER, D., HEMPEL, P., KARCZEWSKI, P. & KRAUSE, E.-G. (1999). Activation of β2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failue. Circulation, 99, 6572.
  • KAUMANN, A.J., LYNHAM, J.A., SANDERS, L., BROWN, A.M. & MOLENAAR, P. (1995). Contribution of differential efficacy to the pharmacology of human β1- and β2-adrenoceptors. Pharmacol. Comm., 6, 215222.
  • KAUMANN, A.J. & MOLENAAR, P. (1997). Modulation of human cardiac function through 4 β-adrenoceptor populations. Naunyn-Schmiedeberg's Arch. Pharmacol., 355, 667681.
  • KAUMANN, A.J. & SANDERS, L. (1993). Both β1- and β2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium. Naunyn-Schmiedeberg's Arch. Pharmacol., 348, 536540.
  • KAUMANN, A.J., SANDERS, L., LYNHAM, J.A., BARTEL, S., KUSCHEL, M., KARCZEWSKI, P. & KRAUSE, E.-G. (1996). β2-Adrenoceptor activation by zinterol causes protein phosphorylation, contractile effects and relaxant effects through a cAMP pathway in human atrium. Mol. Cell. Biochem., 163/164, 113123.
  • KILTS, J.D., GERHARDT, M.A., RICHARDSON, M.D., SREERAM, G., MACKENSEN, G.B., GROCOTT, H.P., WHITE, W.D., DAVIS, R.D., NEWMAN, M.F., REVES, J.G., SCHWINN, D.A. & KWATRA, M.M. (2000). β2-Adrenergic and several other G protein-coupled receptors in human atrial membranes activate both Gs and Gi. Circ. Res., 87, 705709.
  • KIM, Y.S., SAINZ, R.D., MOLENAAR, P. & SUMMERS, R.J. (1991). Characterization of β1- and β2-adrenoceptors in rat skeletal muscles. Biochem. Pharmacol., 42, 17831789.
  • KIM, Y.S., SAINZ, R.D., SUMMERS, R.J. & MOLENAAR, P. (1992). Cimaterol reduces β-adrenergic receptor density in rat skeletal muscles. J. Anim. Sci., 70, 115122.
  • KISSEL, J.T., MCDERMOTT, M.P., MENDELL, J.R., KING, W.M., PANDYA, S., GRIGGS, R.C. & TAWIL, R. (2001). Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology., 57, 14341440.
  • KISSEL, J.T., MCDERMOTT, M.P., NATARAJAN, R., MENDELL, J.R., PANDYA, S., KING, W.M., GRIGGS, R.C. & TAWIL, R. (1998). Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology, 50, 14021406.
  • KRAUSE, E.-G., BARTEL, S., VETTER, D., KARCZEWSKI, P., RUSSELL, F.D., KAUMANN, A.J. & MOLENAAR, P. (2004). Both β1- and β2-adrenoceptors mediate increases in contractile force and hastening of relaxation in human atrium. J. Mol. Cell. Cardiol., 37, 229.
  • LEMOINE, H., OVERLACK, C., KÖHL, A., WORTH, H & REINHARDT, D. (1992). Formoterol, fenoterol, and salbutamol as partial agonists for relaxation of maximally contracted guinea pig tracheae: comparison of relaxation with receptor binding. Lung, 170, 163180.
  • LEMOINE, H., OVERLACK, C., WORTH, H. & REINHARDT, D. (1991). Increased muscarinic prestimulation of guinea-pig tracheal strips decreases potency and intrinsic activity (ISA) of synthetic β2-sympathomimetics. Comparison of relaxation with receptor binding and adenylate stimulation. Naunyn-Schmiedeberg's Arch. Pharmacol., 343, R98.
  • LIGGETT, S.B., TEPE, N.M., LORENZ, J.N., CANNING, A.M., JANTZ, T.D., MITARIAI, S., YATANI, A. & DORN II, G.W. (2000). Early and delayed consequences of β2-adrenergic receptor overexpression in mouse hearts. Critical role for expression level. Circ. Res., 101, 17071714.
  • LOWE, M.D., ROWLAND, E., BROWN, M.J. & GRACE, A.A. (2001). β2 Adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium. Heart, 86, 4551.
  • METTAUER, B., ROULEAU, J.-L. & BURGESS, J.H. (1985). Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am. Heart J., 109, 840847.
  • MOLENAAR, P., BARTEL, S., COCHRANE, A., VETTER, D., JALALI, H., POHLNER, P., BURRELL, K., KARCZEWSKI, P., KRAUSE, E.-G. & KAUMANN, A. (2000). Both β2- and β1-adrenergic receptors mediate hastened relaxation and phosphorylation of phospholamban and troponin I in ventricular myocardium of Fallot infants, consistent with selective coupling of β2-adrenergic receptors to Gs-protein. Circulation, 102, 18141821.
  • MOLENAAR, P. & PARSONAGE, W.A. (2005). Fundamental considerations of β-adrenoceptor subtypes in human heart failure. Trends Pharmacol. Sci., 26, 368375.
  • MORISCO, C., ZEBROWSKI, D.C., VATNER, D.E., VATNER, S.F. & SADOSHIMA, J. (2001). Adrenergic cardiac hypertrophy is mediated primarily by the β1-subtype in the rat heart. J. Mol. Cell. Cardiol., 33, 561573.
  • NAVEGANTES, L.C.C., RESANO, N.M.Z., MIGLIORINI, R.H. & KETTELHUT, I.C. (2001). Catecholamines inhibit Ca2+-dependent proteolysis in rat skeletal muscle through β2-adrenoceptors and cAMP. Am. J. Physiol. Endocrinol. Metab., 281, E449E454.
  • NEWHOUSE, M.T., CHAPMAN, K.R., MCCALLUM, A.L., ABBOUD, R.T., BOWIE, D.M., HODDER, R.V., PARÉ, P.D., MESIC-FUCHS, H. & MOLFINO, N.A. (1996). Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Chest, 110, 595603.
  • ROUX, F.J., GRANDORDY, B. & DOUGLAS, J.S. (1996). Functional and binding characteristics of long-acting β2-agonists in lung and heart. Am. J. Resp. Crit. Care. Med., 153, 14891495.
  • RYALL, J.G., SILLENCE, M.N. & LYNCH, G.S. (2006). Systemic administration of β2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br. J. Pharmacol., 147, 587595 (this issue).
  • SALPETER, S.R. (2004). Cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease. A systematic review. Drugs Aging, 21, 405414.
  • SARSERO, D. & MOLENAAR, P. (1995). Effects of chronic infusion of (−)-isoprenaline on rat cardiac muscarinic (M2)-cholinoceptors and β1- and β2-adrenoceptors. J. Auton. Pharmacol., 15, 239255.
  • TESCHEMACHER, A. & LEMOINE, H. (1999). Kinetic analysis of drug–receptor interactions of long-acting β2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J. Pharmacol. Exp. Ther., 28, 10841092.
  • TROFAST, J., ÖSTERBERG, K., KÄLLSTRÖM, B.-L. & WALDECK, B. (1991). Steric aspects of agonism and antagonism at β-adrenoceptors: synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers. Chirality, 3, 443450.
  • XIAO, R.-P. (2001). β-Adrenergic signaling in the heart: dual coupling of the β2-adrenergic receptor to Gs and Gi proteins. Sci. STKE, 104, re15.
  • XIAO, R.-P., ZHU, W., ZHANG, M., CHAKIR, K., BOND, R., LAKATTA, E.G. & CHENG, H. (2004). Subtype-specific β-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol. Sci., 25, 358365.
  • ZHENG, M., ZHU, W., HAN, Q. & XIAO, R.-P. (2005). Emerging concepts and therapeutic implications of β-adrenergic receptor subtype signaling. Pharmacol. Ther., 108, 257268.